83 related articles for article (PubMed ID: 28196064)
1. MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.
Yip C; Foidart P; Somja J; Truong A; Lienard M; Feyereisen E; Schroeder H; Gofflot S; Donneau AF; Collignon J; Delvenne P; Sounni NE; Jerusalem G; Noël A
Br J Cancer; 2017 Mar; 116(6):742-751. PubMed ID: 28196064
[TBL] [Abstract][Full Text] [Related]
2. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
[TBL] [Abstract][Full Text] [Related]
3. PDZK1 suppresses TNBC development and sensitizes TNBC cells to erlotinib via the EGFR pathway.
Ma Y; Fang Z; Zhang H; Qi Y; Mao Y; Zheng J
Cell Death Dis; 2024 Apr; 15(3):199. PubMed ID: 38604999
[TBL] [Abstract][Full Text] [Related]
4. Targeted blocking of EGFR and GLUT1 by compound H reveals a new strategy for treatment of triple-negative breast cancer and nasopharyngeal carcinoma.
Wang C; Li Z; Zhai H; Shen X; Li F; Zhang Q; Li D; Hou H
Eur J Pharm Sci; 2024 May; 198():106789. PubMed ID: 38710335
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy promotes tumour cell hybridization in vivo.
Yan B; Wang J; Liu L
Tumour Biol; 2016 Apr; 37(4):5025-30. PubMed ID: 26537586
[TBL] [Abstract][Full Text] [Related]
6. Mode of Action Analyses of Neferine, a Bisbenzylisoquinoline Alkaloid of Lotus (
Kadioglu O; Law BYK; Mok SWF; Xu SW; Efferth T; Wong VKW
Front Pharmacol; 2017; 8():238. PubMed ID: 28529482
[TBL] [Abstract][Full Text] [Related]
7. Sensitization of breast cancer cells to paclitaxel by dichloroacetate through inhibiting autophagy.
Wang M; Liao C; Hu Y; Qinwen Pan ; Jiang J
Biochem Biophys Res Commun; 2017 Jul; 489(2):103-108. PubMed ID: 28528979
[TBL] [Abstract][Full Text] [Related]
8. TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer.
Yardley DA; Arrowsmith ER; Daniel BR; Eakle J; Brufsky A; Drosick DR; Kudrik F; Bosserman LD; Keaton MR; Goble SA; Bubis JA; Priego VM; Pendergrass K; Manalo Y; Bury M; Gravenor DS; Rodriguez GI; Inhorn RC; Young RR; Harwin WN; Silver C; Hainsworth JD; Burris HA
Breast Cancer Res Treat; 2017 Aug; 164(3):649-658. PubMed ID: 28508185
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.
Wilson RH; Evans TJ; Middleton MR; Molife LR; Spicer J; Dieras V; Roxburgh P; Giordano H; Jaw-Tsai S; Goble S; Plummer R
Br J Cancer; 2017 Mar; 116(7):884-892. PubMed ID: 28222073
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab in metastatic breast cancer after complete remission: an expensive commitment for an entire life?
Bernardi D; Stefani M; Boccalon M; Raiti C
Curr Oncol; 2017 Feb; 24(1):e76-e77. PubMed ID: 28270736
[No Abstract] [Full Text] [Related]
11. Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity
Rebouissou S; La Bella T; Rekik S; Imbeaud S; Calatayud AL; Rohr-Udilova N; Martin Y; Couchy G; Bioulac-Sage P; Grasl-Kraupp B; de Koning L; Ganne-Carrié N; Nault JC; Ziol M; Zucman-Rossi J
Clin Cancer Res; 2017 Aug; 23(15):4364-4375. PubMed ID: 28246274
[No Abstract] [Full Text] [Related]
12. Treatment of choice for patients with EGFR mutation-positive non-small cell lung carcinoma presenting with choroidal metastases: radiotherapy or TKIs?
Maskell D; Geropantas K; Kouroupis M; Glenn A; Ajithkumar T
Can J Ophthalmol; 2017 Feb; 52(1):e22-e25. PubMed ID: 28237165
[TBL] [Abstract][Full Text] [Related]
13. Aptamer-Conjugated Chitosan-Anchored Liposomal Complexes for Targeted Delivery of Erlotinib to EGFR-Mutated Lung Cancer Cells.
Li F; Mei H; Xie X; Zhang H; Liu J; Lv T; Nie H; Gao Y; Jia L
AAPS J; 2017 May; 19(3):814-826. PubMed ID: 28233244
[TBL] [Abstract][Full Text] [Related]
14. Combination of ruthenium(II)-arene complex [Ru(η
Berndsen RH; Weiss A; Abdul UK; Wong TJ; Meraldi P; Griffioen AW; Dyson PJ; Nowak-Sliwinska P
Sci Rep; 2017 Feb; 7():43005. PubMed ID: 28223694
[TBL] [Abstract][Full Text] [Related]
15. MiR-30 Family Potentially Targeting PI3K-SIAH2 Predicted Interaction Network Represents a Novel Putative Theranostic Panel in Non-small Cell Lung Cancer.
Chan LW; Wang F; Meng F; Wang L; Wong SC; Au JS; Yang S; Cho WC
Front Genet; 2017; 8():8. PubMed ID: 28210267
[TBL] [Abstract][Full Text] [Related]
16. Expression of microRNA-30c via lentivirus vector inhibits the proliferation and enhances the sensitivity of highly aggressive ccRCC Caki-1 cells to anticancer agents.
Yang H; Song E; Shen G; Zhu T; Jiang T; Shen H; Niu L; Wang B; Lu Z; Qian J
Onco Targets Ther; 2017; 10():579-590. PubMed ID: 28203091
[TBL] [Abstract][Full Text] [Related]
17. The Influence of Race/Ethnicity on the Transcriptomic Landscape of Uterine Fibroids.
Chuang TD; Ton N; Rysling S; Quintanilla D; Boos D; Gao J; McSwiggin H; Yan W; Khorram O
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686244
[TBL] [Abstract][Full Text] [Related]
18. Molecular Mechanisms Driven by MT4-MMP in Cancer Progression.
Muñoz-Sáez E; Moracho N; Learte AIR; Collignon A; Arroyo AG; Noel A; Sounni NE; Sánchez-Camacho C
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373092
[TBL] [Abstract][Full Text] [Related]
19. A Systematic Study on Zinc-Related Metabolism in Breast Cancer.
Qu Z; Liu Q; Kong X; Wang X; Wang Z; Wang J; Fang Y
Nutrients; 2023 Mar; 15(7):. PubMed ID: 37049543
[TBL] [Abstract][Full Text] [Related]
20. EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer.
Lee KJ; Wright G; Bryant H; Wiggins LA; Schuler M; Gassman NR
Cancer Drug Resist; 2020; 3(4):980-991. PubMed ID: 35582228
[No Abstract] [Full Text] [Related]
[Next] [New Search]
